The Impact of Immunotherapy Use in Stage IIIA (T1-2N2) NSCLC: A Nationwide Analysis.

Wong LY, Liou DZ, Roy M, Elliott IA, Backhus LM, Lui NS, Shrager JB, Berry MF

Open source

DOI
10.1016/j.jtocrr.2024.100654
Published
2024 Mar
Container
JTO clinical and research reports
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.jtocrr.2024.100654,
  title = {The Impact of Immunotherapy Use in Stage IIIA (T1-2N2) NSCLC: A Nationwide Analysis.},
  author = {Wong LY and Liou DZ and Roy M and Elliott IA and Backhus LM and Lui NS and Shrager JB and Berry MF},
  year = {2024},
  journal = {JTO clinical and research reports},
  doi = {10.1016/j.jtocrr.2024.100654},
  url = {https://doi.org/10.1016/j.jtocrr.2024.100654}
}

RIS

TY  - JOUR
TI  - The Impact of Immunotherapy Use in Stage IIIA (T1-2N2) NSCLC: A Nationwide Analysis.
AU  - Wong LY
AU  - Liou DZ
AU  - Roy M
AU  - Elliott IA
AU  - Backhus LM
AU  - Lui NS
AU  - Shrager JB
AU  - Berry MF
PY  - 2024
JO  - JTO clinical and research reports
DO  - 10.1016/j.jtocrr.2024.100654
UR  - https://doi.org/10.1016/j.jtocrr.2024.100654
ER  - 

APA

LY, W., DZ, L., M, R., IA, E., LM, B., NS, L., JB, S., & MF, B. (2024). The Impact of Immunotherapy Use in Stage IIIA (T1-2N2) NSCLC: A Nationwide Analysis.. JTO clinical and research reports. https://doi.org/10.1016/j.jtocrr.2024.100654

Source records